Literature DB >> 23385950

Lipid changes in Kenyan HIV-1-infected infants initiating highly active antiretroviral therapy by 1 year of age.

Agnes Langat1, Sarah Benki-Nugent, Dalton Wamalwa, Ken Tapia, Evelyn Ngugi, Lara Diener, Barbra A Richardson, Ann Melvin, Grace C John-Stewart.   

Abstract

BACKGROUND: Early highly active antiretroviral therapy (HAART) is recommended for HIV-1-infected infants. There are limited data on lipid changes during infant HAART.
METHODS: Nonfasting total (TC), low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol and triglycerides (TG) were measured at 0, 6 and 12 months. Correlates of lipid levels and changes post-HAART were assessed using linear regression.
RESULTS: Among 115 infants, pre-HAART median age was 3.8 months, CD4% was 19% and weight-for-age Z score was -2.42. Pre-HAART median lipid levels were: TC, 108.7 mg/dL; LDL, 42.5 mg/dL; HDL, 29.4 mg/dL and TG, 186.9 mg/dL. Few infants had abnormally high TC (6.2%) or LDL (5.6%), but many had low HDL (76.5%) or high TG (69.6%). Higher pre-HAART weight-for-age and height-for-age Z scores were each associated with higher pre-HAART TC (P = 0.04 and P = 0.01) and LDL (P = 0.02 and P = 0.008). From 0 to 6 months post-HAART, TC (P < 0.0001), LDL (P < 0.0001) and HDL (P < 0.0001) increased significantly, and 23.1% (P = 0.002), 14.0% (P = 0.2), 31.3% (P < 0.0001) and 50.8% (P = 0.2) of infants had abnormally high TC, high LDL, low HDL and high TG, respectively. Changes in TC and HDL were each associated with higher gain in weight-for-age Z score (P = 0.03 and P = 0.01) and height-for-age Z score (P = 0.01 and P = 0.007). Increased change in LDL was associated with higher gain in height-for-age Z score (P = 0.03). Infants on protease inhibitor-HAART had smaller HDL increase (P = 0.004).
CONCLUSIONS: Infants had substantive increases in lipids, which correlated with growth. Increases in HDL were attenuated by protease inhibitor-HAART. It is important to determine clinical implications of these changes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385950      PMCID: PMC3737429          DOI: 10.1097/INF.0b013e31828afb2a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  33 in total

1.  Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.

Authors:  Rohan Hazra; Rachel A Cohen; René Gonin; Jacqueline P Monteiro; Cristina B Hofer; Marinella D Negra; Noris P Ruz
Journal:  AIDS       Date:  2012-01-14       Impact factor: 4.177

2.  Fasting might not be necessary before lipid screening: a nationally representative cross-sectional study.

Authors:  Michael J Steiner; Asheley Cockrell Skinner; Eliana M Perrin
Journal:  Pediatrics       Date:  2011-08-01       Impact factor: 7.124

3.  Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

Authors:  Avy Violari; Jane C Lindsey; Michael D Hughes; Hilda A Mujuru; Linda Barlow-Mosha; Portia Kamthunzi; Benjamin H Chi; Mark F Cotton; Harry Moultrie; Sandhya Khadse; Werner Schimana; Raziya Bobat; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Paul Palumbo
Journal:  N Engl J Med       Date:  2012-06-21       Impact factor: 91.245

4.  Survival benefit of early infant antiretroviral therapy is compromised when diagnosis is delayed.

Authors:  Dalton Wamalwa; Sarah Benki-Nugent; Agnes Langat; Ken Tapia; Evelyn Ngugi; Jennifer A Slyker; Barbra A Richardson; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2012-07       Impact factor: 2.129

5.  The metabolic syndrome, an epidemic among HIV-infected patients on HAART.

Authors:  D J Jevtović; G Dragović; D Salemović; J Ranin; O Djurković-Djaković
Journal:  Biomed Pharmacother       Date:  2008-10-23       Impact factor: 6.529

6.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

7.  Serum lipid profile in malnourished Nigerian children in Zaria.

Authors:  A Akuyam; H S Isah; W N Ogala
Journal:  Niger Postgrad Med J       Date:  2008-09

Review 8.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 9.  HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.

Authors:  Donald P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2008-09-01       Impact factor: 3.731

10.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

View more
  1 in total

1.  Dyslipidemia, Diet and Physical Exercise in Children on Treatment With Antiretroviral Medication in El Salvador: A Cross-sectional Study.

Authors:  Michela Sonego; Maria José Sagrado; Gustavo Escobar; Marzia Lazzerini; Estefanie Rivas; Rocio Martín-Cañavate; Elsy Pérez de López; Sandra Ayala; Luis Castaneda; Pilar Aparicio; Estefanía Custodio
Journal:  Pediatr Infect Dis J       Date:  2016-10       Impact factor: 2.129

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.